ClinicalTrials.Veeva

Menu
F

Fresno Clinical Research Center | Fresno, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Selonsertib
MGL-3196
LY3298176
Cenicriviroc
Relamorelin
EDP-305
HTD1801
Obeticholic Acid
Cilofexor
Elafibranor

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 16 total trials

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling
Non-Alcoholic Fatty Liver Disease
Drug: Resmetirom

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Procedure: Liver Biopsy
Drug: MGL-3196

This is a randomized, blinded, placebo-controlled study of BOS-580 in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohe...

Enrolling
Nonalcoholic Steatohepatitis (NASH)
Drug: Placebo
Drug: BOS-580

Trial sponsors

Gilead Sciences logo
Madrigal Pharmaceuticals logo
Allergan logo
Boston Scientific logo
Enanta Pharmaceuticals logo
Genfit logo
H
I
Lilly logo
Mirum Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems